Otsuka Holdings Full Year 2024 Earnings: EPS Beats Expectations

Otsuka Holdings (TSE:4578) Full Year 2024 Results

Key Financial Results

• Revenue: JP¥2.33t (up 15% from FY 2023).
• Net income: JP¥343.1b (up 182% from FY 2023).
• Profit margin: 15% (up from 6.0% in FY 2023).
• EPS: JP¥634 (up from JP¥224 in FY 2023).

4578 Products In Clinical Trials

• Phase II: 3.
• Phase III: 14.

4578 Post-Clinical Trial Products

• Pre-registration: 2.
• Approved (during full year): 3.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Otsuka Holdings EPS Beats Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 24%.

The primary driver behind last 12 months revenue was the Pharmaceuticals segment contributing a total revenue of JP¥1.63t (70% of total revenue). The largest operating expense was General & Administrative costs, amounting to JP¥958.3b (72% of total expenses). Explore how 4578's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 1.6% p.a. on average during the next 3 years, compared to a 4.1% growth forecast for the Pharmaceuticals industry in Japan.

Performance of the Japanese Pharmaceuticals industry.

The company's shares are up 1.8% from a week ago.

Valuation

Our analysis of Otsuka Holdings based on 6 different valuation metrics shows it might be undervalued. To access our thorough examination of analyst consensus click here and discover the expected future direction of the company.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.